Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
NCT07750158
This study is recruiting at 13 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The primary objective of this study is to evaluate the effectiveness of zanzalintinib + Pembrolizumab (+) berahyaluronidase alfa and zanzalintinib alone compared with placebo.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Colorectal Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Exelixis
- Last updated on ClinicalTrials.gov
- September 21, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Iowa · 1
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Council Bluffs · Council Bluffs, IA
Nebraska · 6
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Grand Island · Grand Island, NE
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Regional · Grand Island, NE
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Bergan · Omaha, NE
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Legacy · Omaha, NE
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Methodist · Omaha, NE
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Papillion · Papillion, NE
New Jersey · 6
- Astera Cancer Care · Bridgewater, NJ
- Astera Cancer Care · East Brunswick, NJ
- Astera Cancer Care · Edison, NJ
- Astera Cancer Care · Monroe, NJ
- Astera Cancer Care · Somerset, NJ
- Astera Cancer Care · Toms River, NJ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.